FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1976988259> ?p ?o ?g. }

• W1976988259 endingPage "455" @default.
• W1976988259 startingPage "449" @default.
• W1976988259 abstract "To summarize safety and tolerability data on orally administered almotriptan from premarketing clinical trials.Almotriptan is a new 5-HT1B/1D receptor agonist similar to sumatriptan in mode of action and therapeutic efficacy. In addition, the safety and tolerability profile of almotriptan has been demonstrated in a number of controlled clinical trials. Sumatriptan is generally safe and well tolerated; however, in controlled clinical trials, it has been associated with chest symptoms (pressure, warmth, and other unpleasant sensations) with an incidence of 3% to 5%.Three phase 1 dose-finding and pharmacokinetic studies in healthy men and women volunteers were reviewed to assess the safety and tolerability of oral almotriptan at single doses ranging from 2 to 200 mg. The objective of one study was to evaluate cardiovascular safety. Two phase 2 trials assessed the safety and tolerability of single doses of 2 to 150 mg in migraine (n=911). Two phase 3 trials assessed the safety and tolerability of a single 12.5-mg oral dose after three attacks (n=910) and repeated doses of 12.5 mg for multiple attacks over the long term (n=747). All studies were conducted in Europe. Data from the United States is currently being analyzed and will be published at a later date.In phase 2 and 3 trials comprising more than 2500 patients with migraine and 15 000 attacks, adverse events were infrequent and mild. The most common events-dizziness, nausea and vomiting, headache, fatigue, paresthesia, and drowsiness-were reported in fewer than 3% of patients. At the recommended therapeutic dose of 12.5 mg, the adverse events profile was not statistically different from placebo. The incidence of chest symptoms was 0.2% in the phase 3 trials. The long-term safety and tolerability profile after treatment of more than 10 000 attacks was similar to that following the single-dose studies. In all clinical trials, almotriptan demonstrated a very favorable adverse event profile, particularly with respect to nonischemic-related chest symptoms.Almotriptan was safe and well tolerated in nearly all adult patients with migraine, with and without aura, enrolled in these studies. The incidence of chest symptoms in preclinical studies was substantially lower than that reported for sumatriptan in premarketing studies, indicating that almotriptan may be better tolerated than sumatriptan at clinically anticipated doses. However, any potential difference in cardiovascular safety between almotriptan and sumatriptan cannot be determined or inferred from this data. Cardiovascular risk profiles for all drugs within this class (triptans) should be considered similar. Only extensive postmarketing data, not currently available, can potentially change this recommendation." @default.
• W1976988259 created "2016-06-24" @default.
• W1976988259 creator A5057290642 @default.
• W1976988259 date "2001-05-06" @default.
• W1976988259 modified "2023-09-23" @default.
• W1976988259 title "Oral Almotriptan in the Treatment of Migraine: Safety and Tolerability" @default.
• W1976988259 cites W1968234092 @default.
• W1976988259 cites W2024395292 @default.
• W1976988259 cites W2036187691 @default.
• W1976988259 cites W2036354453 @default.
• W1976988259 cites W2046551008 @default.
• W1976988259 cites W2061167989 @default.
• W1976988259 doi "https://doi.org/10.1046/j.1526-4610.2001.01082.x" @default.
• W1976988259 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/11380642" @default.
• W1976988259 hasPublicationYear "2001" @default.
• W1976988259 type Work @default.
• W1976988259 sameAs 1976988259 @default.
• W1976988259 citedByCount "48" @default.
• W1976988259 countsByYear W19769882592012 @default.
• W1976988259 countsByYear W19769882592013 @default.
• W1976988259 countsByYear W19769882592015 @default.
• W1976988259 countsByYear W19769882592019 @default.
• W1976988259 countsByYear W19769882592021 @default.
• W1976988259 countsByYear W19769882592022 @default.
• W1976988259 crossrefType "journal-article" @default.
• W1976988259 hasAuthorship W1976988259A5057290642 @default.
• W1976988259 hasConcept C126322002 @default.
• W1976988259 hasConcept C170493617 @default.
• W1976988259 hasConcept C197934379 @default.
• W1976988259 hasConcept C2778375690 @default.
• W1976988259 hasConcept C2778541695 @default.
• W1976988259 hasConcept C2778871607 @default.
• W1976988259 hasConcept C2778938600 @default.
• W1976988259 hasConcept C2780580376 @default.
• W1976988259 hasConcept C2780852908 @default.
• W1976988259 hasConcept C42219234 @default.
• W1976988259 hasConcept C535046627 @default.
• W1976988259 hasConcept C71924100 @default.
• W1976988259 hasConcept C98274493 @default.
• W1976988259 hasConceptScore W1976988259C126322002 @default.
• W1976988259 hasConceptScore W1976988259C170493617 @default.
• W1976988259 hasConceptScore W1976988259C197934379 @default.
• W1976988259 hasConceptScore W1976988259C2778375690 @default.
• W1976988259 hasConceptScore W1976988259C2778541695 @default.
• W1976988259 hasConceptScore W1976988259C2778871607 @default.
• W1976988259 hasConceptScore W1976988259C2778938600 @default.
• W1976988259 hasConceptScore W1976988259C2780580376 @default.
• W1976988259 hasConceptScore W1976988259C2780852908 @default.
• W1976988259 hasConceptScore W1976988259C42219234 @default.
• W1976988259 hasConceptScore W1976988259C535046627 @default.
• W1976988259 hasConceptScore W1976988259C71924100 @default.
• W1976988259 hasConceptScore W1976988259C98274493 @default.
• W1976988259 hasIssue "5" @default.
• W1976988259 hasLocation W19769882591 @default.
• W1976988259 hasLocation W19769882592 @default.
• W1976988259 hasOpenAccess W1976988259 @default.
• W1976988259 hasPrimaryLocation W19769882591 @default.
• W1976988259 hasRelatedWork W140232390 @default.
• W1976988259 hasRelatedWork W1970872264 @default.
• W1976988259 hasRelatedWork W1973349312 @default.
• W1976988259 hasRelatedWork W1985762969 @default.
• W1976988259 hasRelatedWork W2006790890 @default.
• W1976988259 hasRelatedWork W2022556905 @default.
• W1976988259 hasRelatedWork W2137547383 @default.
• W1976988259 hasRelatedWork W2415136871 @default.
• W1976988259 hasRelatedWork W2428645761 @default.
• W1976988259 hasRelatedWork W4251165208 @default.
• W1976988259 hasVolume "41" @default.
• W1976988259 isParatext "false" @default.
• W1976988259 isRetracted "false" @default.
• W1976988259 magId "1976988259" @default.
• W1976988259 workType "article" @default.